

Claim Listing

1. (Previously presented) A method for treating a human with cancer, comprising administering to the human with cancer a composition comprising between approximately 10^{-2} mg to approximately 10^{-8} mg of neuraminidase, wherein the method further comprises multiple per day administrations of the composition.

2. (Previously presented) The method of Claim 1, wherein the composition comprises neuraminidase dissolved in a phenol-saline solution.

Claim 3 cancelled.

4. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered systemically.

5. (Previously presented) The method of Claim 1, wherein the neuraminidase composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.

6. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered sublingually.

7. (Previously presented) The method of Claim 5, wherein the neuraminidase composition is administered nasally.

8. (Previously presented) The method of Claim 1, wherein cancer is a solid tumor.

9. (Previously presented) The method of Claim 8, wherein cancer is prostate cancer, pancreatic cancer, melanoma, breast cancer, colon cancer, lymphoma, esophageal cancer, lung cancer, testicular cancer, or brain cancer.

Claims 10, 11 and 12 (cancelled)

13. (Previously presented) The method of Claim 1, wherein less than approximately 10^{-2} mg neuraminidase is administered.

14. (Previously presented) The method of Claim 1, wherein approximately 10^{-3} mg to 10^{-7} mg neuraminidase is administered.

15. (Previously presented) The method of Claim 1, wherein approximately 10^{-4} mg neuraminidase is administered.

16. (Original) The method of Claim 1, wherein the neuraminidase is administered one to eight times per day.

17. (Previously presented) A method for treating a human with cancer, comprising administering to the human a composition consisting essentially of between approximately 10^{-2} mg to approximately 10^{-8} mg of neuraminidase wherein the method further comprises multiple per day administrations of the composition.